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Abstract 
2020 The Authors Dermal fibroblasts were donated by a 43 year old male patient with clinically diagnosed 
familial amyotrophic lateral sclerosis (ALS), carrying the SOD1E101G mutation. The induced pluripotent 
stem cell (iPSC) line UOWi007-A was generated using repeated mRNA transfections for pluripotency 
transcription factors Oct4, Klf4, Sox2, c-Myc, Lin28 and Nanog. The iPSCs carried the SOD1E101G 
genotype and had a normal karyotype, expressed expected pluripotency markers and were capable of in 
vitro differentiation into endodermal, mesodermal and ectodermal lineages. This iPSC line may be useful 
for investigating familial ALS resulting from a SOD1 E101G mutation. 
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A B S T R A C T
Dermal fibroblasts were donated by a 43 year old male patient with clinically diagnosed familial amyotrophic lateral sclerosis (ALS), carrying the SOD1E101G
mutation. The induced pluripotent stem cell (iPSC) line UOWi007-A was generated using repeated mRNA transfections for pluripotency transcription factors Oct4,
Klf4, Sox2, c-Myc, Lin28 and Nanog. The iPSCs carried the SOD1E101G genotype and had a normal karyotype, expressed expected pluripotency markers and were
capable of in vitro differentiation into endodermal, mesodermal and ectodermal lineages. This iPSC line may be useful for investigating familial ALS resulting from a
SOD1 E101G mutation.
Resource table











Type of cell line iPSC
Origin Human
Additional origin info Age: 43
Sex: Male




Transgene free, mRNA based reprogramming with Oct4,
Klf4, Sox2, c-Myc, Lin28 and Nanog.
Genetic Modification Yes
Type of Modification Hereditary
Associated disease Amyotrophic lateral sclerosis
Gene/locus SOD1E101G
Method of modification N/A












Ethical approval HE13/272 University of Wollongong Human Research
Ethics Committee
1. Resource utility
This iPSC line can be used to investigate familial ALS resulting from
a SOD1E101G mutation. This resource is available under request owing
to the Materials Transfer Agreement in place.
2. Resource details
Dermal fibroblasts were obtained from a 43 year old male patient by
Macquarie University, Australia. The patient was clinically diagnosed
with familial amyotrophic lateral sclerosis (ALS), heterozygous for the
SOD1E101G mutation (also termed SOD1E100G due to N-terminal me-
thionine cleavage). The SOD1 gene encodes the cytosolic antioxidant
enzyme, copper-zinc superoxide dismutase (SOD1). Mutant SOD1E101G
retains the wild-type-like dismutase activity of the enzyme with pa-
thology hypothesized to be due to misfolding and subsequent ag-
gregation of mutant SOD1 (Valentine et al., 2005; Farrawell et al.,
https://doi.org/10.1016/j.scr.2020.101701
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Reprogramming was performed using repeated mRNA transfections
for pluripotency transcription factors Oct4, Klf4, Sox2, c-Myc, Lin28
and Nanog. The first iPSC colonies appeared on day 14 and were iso-
lated on day 17 for expansion and characterisation, with clone 2
(UOWi007-A) selected following confirmation of pluripotency. The
UOWi007-A line was authenticated against its parental fibroblast line
via short tandem repeat (STR) profiling, with sequencing confirming
the presence of the SOD1E101G mutation (Fig. 1A). The UOWi007-A
colonies had a normal karyotype (Fig. 1B), with no abnormalities de-
tected in 15 cells at 400 bands per haploid set and had characteristic
stem cell morphology (Fig. 1C). Immunocytochemical analysis con-
firmed expression of pluripotency markers Oct4, SSEA-4 and TRA-1-60
(Fig. 1D). Transcription of endogenous pluripotency genes NANOG and
POU5F1 (Oct4) by quantitative RT-PCR (RT-qPCR) showed a 360 and
2700 fold increase, respectively, in UOWi007-A in comparison to
Fig. 1. Characterization of iPSC line UOWi007-A.
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parental fibroblasts (Fig. 1E) and similar expression levels compared to
another iPSC line UOWi002-A (Muñoz et al., 2018). In addition, plur-
ipotency was assessed using the hPSC Scorecard assay, with an upre-
gulation of mesodermal, endodermal and ectodermal specific genes and
a downregulation of genes associated with pluripotency (Fig. 1F).
3. Materials and methods
3.1. Reprogramming of human dermal fibroblasts
Dermal fibroblasts were cultured in Dulbecco's Modified Eagle
Medium F12 (DMEM/F12, Thermo Fisher Scientific) with 1x Non-
Essential Amino Acids (Thermo Fisher Scientific) and 10% foetal bovine
serum (Interpath) at 37 °C and 5% CO2. Fibroblasts were reprogrammed
using StemMACS mRNA Reprogramming Kit (Myltenyi Biotec #130-
104-460) following the manufacture's protocol. Spontaneous iPSC co-
lonies were isolated and expanded into individual iPSC lines (clones).
Established iPSC clones were maintained in TeSR-E8™ (Stemcell
Technologies) on Matrigel-coated plates (Corning) at 37 °C and 5% CO2
and passaged (1:5) using dispase (Stemcell Technologies) (See Table 1).
The study was approved by the University of Wollongong Human Ethics
Committee (HE 13/272).
3.2. Sequencing
Genomic DNA was extracted using the ISOLATE II Genomic DNA Kit
(Bioline), with DNA amplified by PCR using MyTaq HS DNA
Polymerase (Bioline) with the SOD1 primers (Table 2). Sequencing re-
actions were performed using the ABI BigDye Terminator v3.1 Ready
Reaction Mix and separated using the 3500xL Genetic Analyzer
(Applied Biosystems). BioEdit (Ibis Therapeutics) was used to analyse
the sequences.
3.3. Karyotyping
Karyotyping was performed at Sullivan Nicolaides Pathology Pty
Ltd (Brisbane, Australia), on iPSCs at passage 24, with 15 metaphase
spreads counted at 400 bphs.
3.4. Immunofluorescence staining
The iPSCs were fixed in 4% paraformaldehyde for 10 min, per-
meabilised with 0.05% Triton-X for 7 min (SSEA-4) or 15 min (Oct4)
and blocked in 10% goat serum for 1 h at 22 °C. Primary antibodies
Oct4 and SSEA-4 (Table 2) were incubated overnight at 4 °C, followed
by secondary antibody (Table 2) for 1 h at 22 °C. Cultures were counter
stained with Reddot2 (1:200, Biotium) for 10 min at 22 °C. For TRA-1-
60 staining, cultures were incubated with TRA-1-60 live stain following
manufacture's protocol. Immunocytochemical preparations were im-
aged with a Leica DMI6000B confocal microscope and acquired using
LAS AF 2.6 software (Leica Microsystems).
3.5. Quantitative polymerase chain reaction (qPCR)
Fibroblast and iPSC RNA was extracted using Tri-Reagent (MRC
Gene) as per manufacture's protocol. Genomic DNA was removed using
the Turbo DNAse kit (Thermo Fisher Scientific) and RNA purity de-
termined using a Nanodrop 2000C. Tetro Reverse Transcriptase kit was
used for cDNA synthesis (Bioline). The expression of POU5F1 and
NANOG was assessed via qPCR using SensiFast SYBR (Bioline) on the
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Fig. 1C
Phenotype Immunocytochemistry Expression of pluripotency markers Oct4, SSEA-4, TRA-1-
60
Fig. 1D
RT-qPCR Cells express POU5F1, NANOG Fig. 1E
Genotype Karyotype (G-banding) and resolution 46XY, resolution: 400 bphs Fig. 1B
Identity Microsatellite PCR (mPCR) OR N/A N/A
STR analysis 18 sites tested, matched Submitted in archive with journal
Mutation analysis (IF APPLICABLE) Sequencing Yes - SOD1E101G mutation Fig. 1A
Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma Luminescence, negative Supplementary file 1
Differentiation potential TaqMan hPSC scorecard Passed Fig. 1F
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info (OPTIONAL) Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
Table 2
Reagents details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Oct4 1:000 Stemcell Technologies Cat# 01550, RRID: AB_1118539
SSEA-4 1:200 Abcam Cat# 16286, RRID: AB_778073
TRA-1-60 1:200 Stemcell Technologies Cat# 60064A, RRID: AB_2686905
Secondary antibodies Alexa Fluor 488 Goat Anti-Mouse IgG (H+L) 1:1000 Thermo Fisher Scientific Cat# A11001, RRID: AB_2534069
Primers
Target Forward/reverse primer (5′−3′)
Sequencing SOD1 CATCAGCCCTAATCCATCTGA/ CGCGACTAACAATCAAAGTGA
Pluripotency Genes (qPCR) POU5F1 GATCACCCTGGGATATACAC/ GCTTTGCATATCTCCTGAAG
NANOG CCAGAACCAGAGAATGAAATC/ TGGTGGTAGGAAGAGTAAAG
House-Keeping Genes (qPCR) GAPDH GAGCACAAGAGGAAGAGAGAGACCC/ GTTGAGCACAGGGTACTTTATTGATGGTACATG
HPRT1 TGACACTGGCAAAACAATGCA/ GGTCCTTTTCACCAGCAAGCT
RRID requirement for antibodies: use http://antibodyregistry.org/ to retrieve RRID for antibodies and include ID in table as shown in examples.
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Corbett RotorGene 3000 (Thermo Fisher Scientific) and normalised to
the expression of housekeeper genes HPRT1 and GAPDH. Difference in
expression was calculated via the ΔΔct method.
3.6. Scorecard
Mesodermal and endodermal differentiation was induced using the
STEMdiff Mesoderm Induction Medium (Stemcell Technologies) and
STEMdiff Definitive Endoderm Kit (Stemcell Technologies), respec-
tively, following the manufacture's protocols. Induction of ectodermal
differentiation was achieved using Neural Induction medium (DMEM/
F12, 1% N2, 0.4% B27, 1% MEM Non-essential amino acids, 1%
GlutaMAX) supplemented with 1 μM LDN193189 (Focus Bioscience) for
2 days. The iPSC colonies were detached with dispase (Thermo Fisher
Scientific) to form embryoid bodies and cultured in Neural Induction
medium supplemented with 3 μM CHIR99021 (Focus Bioscience) and
2 μM SB431542 (Focus Bioscience) for 7 days. From each culture, cDNA
was mixed at a ratio of 1:1:1, with 1 μg analysed with the TaqMan hPSC
Scorecard (Thermo Fisher Scientific) following the manufacturer's
protocol.
3.7. STR analysis
STR analysis of 18 locations was performed at Garvan Molecular
Genetics Institute (Darlinghurst, Australia).
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